Work is ongoing to evaluate the reproducibility of these findings in a larger cohort of patients with low or high-grade gliomas, in addition to comparing the specificity of CSF D-2-HG versus imaging or IDH1 ddPCR from cell-free DNA for delineating pseudoprogression from progression. Here, IDH1 is linked to glioma.